Extracellular Vesicle-Based SARS-CoV-2 Vaccine
Messenger ribonucleic acid (RNA) vaccines are mainly used as SARS-CoV-2 vaccines. Despite several issues concerning storage, stability, effective period, and side effects, viral vector vaccines are widely used for the prevention and treatment of various diseases. Recently, viral vector-encapsulated...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/3/539 |
| _version_ | 1827747397650874368 |
|---|---|
| author | Yasunari Matsuzaka Ryu Yashiro |
| author_facet | Yasunari Matsuzaka Ryu Yashiro |
| author_sort | Yasunari Matsuzaka |
| collection | DOAJ |
| description | Messenger ribonucleic acid (RNA) vaccines are mainly used as SARS-CoV-2 vaccines. Despite several issues concerning storage, stability, effective period, and side effects, viral vector vaccines are widely used for the prevention and treatment of various diseases. Recently, viral vector-encapsulated extracellular vesicles (EVs) have been suggested as useful tools, owing to their safety and ability to escape from neutral antibodies. Herein, we summarize the possible cellular mechanisms underlying EV-based SARS-CoV-2 vaccines. |
| first_indexed | 2024-03-11T05:47:52Z |
| format | Article |
| id | doaj.art-263c7057a8c44a1e96d60370e4d236c1 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T05:47:52Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-263c7057a8c44a1e96d60370e4d236c12023-11-17T14:17:28ZengMDPI AGVaccines2076-393X2023-02-0111353910.3390/vaccines11030539Extracellular Vesicle-Based SARS-CoV-2 VaccineYasunari Matsuzaka0Ryu Yashiro1Division of Molecular and Medical Genetics, The Institute of Medical Science, Center for Gene and Cell Therapy, University of Tokyo, Minato-ku, Tokyo 108-8639, JapanAdministrative Section of Radiation Protection, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, JapanMessenger ribonucleic acid (RNA) vaccines are mainly used as SARS-CoV-2 vaccines. Despite several issues concerning storage, stability, effective period, and side effects, viral vector vaccines are widely used for the prevention and treatment of various diseases. Recently, viral vector-encapsulated extracellular vesicles (EVs) have been suggested as useful tools, owing to their safety and ability to escape from neutral antibodies. Herein, we summarize the possible cellular mechanisms underlying EV-based SARS-CoV-2 vaccines.https://www.mdpi.com/2076-393X/11/3/539drug deliveryexosomesextracellular vesicleslipid nanoparticleSARS-CoV-2viral vector |
| spellingShingle | Yasunari Matsuzaka Ryu Yashiro Extracellular Vesicle-Based SARS-CoV-2 Vaccine Vaccines drug delivery exosomes extracellular vesicles lipid nanoparticle SARS-CoV-2 viral vector |
| title | Extracellular Vesicle-Based SARS-CoV-2 Vaccine |
| title_full | Extracellular Vesicle-Based SARS-CoV-2 Vaccine |
| title_fullStr | Extracellular Vesicle-Based SARS-CoV-2 Vaccine |
| title_full_unstemmed | Extracellular Vesicle-Based SARS-CoV-2 Vaccine |
| title_short | Extracellular Vesicle-Based SARS-CoV-2 Vaccine |
| title_sort | extracellular vesicle based sars cov 2 vaccine |
| topic | drug delivery exosomes extracellular vesicles lipid nanoparticle SARS-CoV-2 viral vector |
| url | https://www.mdpi.com/2076-393X/11/3/539 |
| work_keys_str_mv | AT yasunarimatsuzaka extracellularvesiclebasedsarscov2vaccine AT ryuyashiro extracellularvesiclebasedsarscov2vaccine |